The Week Ahead: UK banks results, Glaxo and AstraZeneca, ECB meeting


Plenty of businesses results in the week for UK banks as well as FTSE100 firms such as GlaxoSmithKline and AstraZeneca.

Fund Strategy looks at some key events shaping the week and what to expect.

Monday 24 April

  • Anglo American (Q1 results)

Tuesday 25 April

  •  St James’s Place 1st quarter new business announcement

Wednesday 26 April

  • Standard Chartered (Q1 results)

The Share Centre investment research analyst Graham Spooner says: “The health of emerging markets is key for the bank, which as a result of its past aggressive expansion has been in restructuring and recovery mode over the past two years.

“Investors will be focussing on costs and hoping that the banking situation is stabilizing. Any comments on the outlook for important countries such as Hong Kong, China and Singapore, along with others in the region will be worth noting.”

  • GlaxoSmithKline (Q1 results)

Spooner says: “After posting a good set of 2016 results investors will expect some of that momentum to flow through into the first quarter of the year.  There will be a positive impact from currency movements but investors will also expect to see sales of new drugs make a bigger contribution to overall sales and help mitigate sales declines of out of patent drugs. Progress reports on R&D projects and expectations of further FDA submissions will be welcomed by investors.”

Thursday 27 April

  • EU economic sentiment & business climate indicators
  • European Central Bank Governing Council – interest rate decision and …
  • Lloyds Banking Group results
  • Schroders results
  • AstraZeneca (Q1 results)

Friday 28 April

  • Barclays (Q1 results)

Spooner says: “Results in February stated that the end of the group’s restructuring is in sight, as is the return to dividend growth. Investors will be hoping for further signs that the firm’s problems are now more in the past.

“As ever the performance of the still important investment banking division will be worth noting. Costs and the outlook for the UK, US and Barclaycard are other areas to concentrate on.”

  • Royal Bank of Scotland (Q1 results)